Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
LaunchEnveric Biosciences Expands Patent Protection for EVM301 Portfolio with New Issuances to Enhance Value-Capture Opportunities.
Nov 04, 2024
CambridgeBiotechnologyHealthcareHealth CareScience And Engineering
Product Description
Enveric Biosciences announces the issuance of five additional US patents, expanding its EVM301 portfolio that focuses on novel neuroplastogens for treating neuropsychiatric disorders. This expansion includes a total of nine issued patents, enhancing their intellectual property backing and drug candidate library.
Company Information
Company
Enveric Biosciences
Location
Cambridge, Massachusetts, United States
About
Enveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric's robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Enveric Biosciences ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.